UK Markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0650+0.0790 (+8.01%)
As of 12:28PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.45
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 32.9300
52-week low 30.2410
50-day moving average 30.5173
200-day moving average 30.4021

Share statistics

Avg vol (3-month) 31.89M
Avg vol (10-day) 32.31M
Shares outstanding 5183.96M
Implied shares outstanding 6N/A
Float 8181.66M
% held by insiders 11.51%
% held by institutions 133.32%
Shares short (13 Oct 2022) 46.29M
Short ratio (13 Oct 2022) 44.83
Short % of float (13 Oct 2022) 43.46%
Short % of shares outstanding (13 Oct 2022) 43.42%
Shares short (prior month 14 Sept 2022) 47.71M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -55.04%
Operating margin (ttm)-38.91%

Management effectiveness

Return on assets (ttm)-12.73%
Return on equity (ttm)-137.90%

Income statement

Revenue (ttm)296.82M
Revenue per share (ttm)1.67
Quarterly revenue growth (yoy)139.60%
Gross profit (ttm)-17.92M
EBITDA -77.69M
Net income avi to common (ttm)-163.37M
Diluted EPS (ttm)-2.7690
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)143.89M
Total cash per share (mrq)0.78
Total debt (mrq)134.31M
Total debt/equity (mrq)215.59
Current ratio (mrq)1.30
Book value per share (mrq)1.67

Cash flow statement

Operating cash flow (ttm)-171.36M
Levered free cash flow (ttm)-130.64M